JP2011500758A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500758A5
JP2011500758A5 JP2010530433A JP2010530433A JP2011500758A5 JP 2011500758 A5 JP2011500758 A5 JP 2011500758A5 JP 2010530433 A JP2010530433 A JP 2010530433A JP 2010530433 A JP2010530433 A JP 2010530433A JP 2011500758 A5 JP2011500758 A5 JP 2011500758A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
alkyloxy
hydroxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500758A (ja
JP5525447B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064243 external-priority patent/WO2009053373A1/en
Publication of JP2011500758A publication Critical patent/JP2011500758A/ja
Publication of JP2011500758A5 publication Critical patent/JP2011500758A5/ja
Application granted granted Critical
Publication of JP5525447B2 publication Critical patent/JP5525447B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530433A 2007-10-26 2008-10-22 Parp阻害剤としてのキノリノン誘導体 Expired - Fee Related JP5525447B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119417.9 2007-10-26
EP07119417 2007-10-26
PCT/EP2008/064243 WO2009053373A1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors

Publications (3)

Publication Number Publication Date
JP2011500758A JP2011500758A (ja) 2011-01-06
JP2011500758A5 true JP2011500758A5 (enExample) 2011-12-08
JP5525447B2 JP5525447B2 (ja) 2014-06-18

Family

ID=39345428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530433A Expired - Fee Related JP5525447B2 (ja) 2007-10-26 2008-10-22 Parp阻害剤としてのキノリノン誘導体

Country Status (6)

Country Link
US (1) US8404713B2 (enExample)
EP (1) EP2215075B1 (enExample)
JP (1) JP5525447B2 (enExample)
ES (1) ES2448870T3 (enExample)
PL (1) PL2215075T3 (enExample)
WO (1) WO2009053373A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2872883A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
BR112017003658B1 (pt) * 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
ES2870203T3 (es) * 2015-06-09 2021-10-26 Onconic Therapeutics Inc Compuesto derivado tricíclico, método para prepararlo y composición farmacéutica que comprende el mismo
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
EP3585783A2 (en) 2016-02-25 2020-01-01 Asceneuron SA Sulfoximine glycosidase inhibitors
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
MX2019010085A (es) 2017-02-24 2019-11-21 Asceneuron S A Inhibidores de la glicosidasa de sulfoximina.
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
EP3672958B1 (en) 2017-08-24 2023-08-02 Asceneuron SA Annulated glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
EP3841093B1 (en) 2018-08-22 2023-06-21 Asceneuron SA Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
US20220143042A1 (en) 2019-02-22 2022-05-12 Asceneuron Sa Fused glycosidase inhibitors
HUE071067T2 (hu) * 2019-07-19 2025-07-28 Astrazeneca Ab PARP1 inhibitorok
DK4003358T3 (da) * 2019-07-26 2026-01-26 Health Research Inc Behandling af cancere med p53-mangel
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
MX2023012039A (es) * 2021-04-12 2024-03-05 Impact Therapeutics Shanghai Inc Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.
CA3216373A1 (en) 2021-04-19 2022-10-27 Lynnie TRZOSS Parp1 inhibitors and uses thereof
AU2022261011A1 (en) * 2021-04-22 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
WO2022223025A1 (zh) * 2021-04-23 2022-10-27 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
CN115232121B (zh) * 2021-04-23 2023-08-29 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
US20240287094A1 (en) * 2021-05-24 2024-08-29 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
CN115403595A (zh) * 2021-05-27 2022-11-29 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药(杭州)有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
US20240400586A1 (en) * 2021-09-30 2024-12-05 Haisco Pharmaceutical Group Co., Ltd. Heteroaryl derivative parp inhibitor and use thereof
CN118043322A (zh) * 2021-09-30 2024-05-14 西藏海思科制药有限公司 含氮杂环衍生物parp抑制剂及其用途
EP4410791A4 (en) * 2021-09-30 2025-10-22 Xizang Haisco Pharmaceutical Co Ltd BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE
CR20240144A (es) 2021-10-01 2024-05-24 Xinthera Inc Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CA3235698A1 (en) * 2021-10-22 2023-04-27 Yao Li Parp-1 degradation agent and use thereof
JP7762306B2 (ja) * 2021-11-19 2025-10-29 康百達(四川)生物医薬科技有限公司 選択的parp1阻害剤およびその用途
JP7804371B2 (ja) * 2021-12-17 2026-01-22 キーセラ(スーチョウ)バイオ-ファーマスーティカルズ カンパニー,リミテッド Parp阻害剤、それを含む医薬組成物及びそれらの使用
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
AU2023209820B2 (en) * 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
EP4469449A4 (en) * 2022-01-27 2026-02-25 Xinthera Inc PARP1 INHIBITORS AND THEIR USES
CA3249318A1 (en) * 2022-01-28 2023-08-03 Xinthera, Inc. PARP1 INHIBITORS AND THEIR USES
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
CA3250945A1 (en) 2022-04-28 2023-11-02 Xinthera, Inc. TRICYCLIC PARP1 INHIBITORS AND THEIR USES
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
AU2023275808A1 (en) * 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
EP4534533A4 (en) * 2022-06-02 2026-04-29 Chengdu Easton Biopharmaceuticals Co Ltd AZAQUINOLINONE DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
CN117917407A (zh) * 2022-10-20 2024-04-23 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
CN120019054A (zh) * 2022-10-20 2025-05-16 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
AU2023383898A1 (en) 2022-11-23 2025-06-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor
KR20250117449A (ko) * 2022-12-23 2025-08-04 제지앙 양리 파마슈티칼 테크놀로지 씨오., 엘티디. Parp1 억제제
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025101892A1 (en) * 2023-11-10 2025-05-15 Astellas Engineered Small Molecules US, Incorporated Poly-adp ribose polymerase (parp) inhibitors and uses thereof
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) * 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (enExample) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
JPS60226862A (ja) 1984-03-26 1985-11-12 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ 抗ウイルス活性ピリダジンアミン類
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) * 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
EP0637306B1 (en) * 1992-04-23 2001-05-30 Merrell Pharmaceuticals Inc. 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy
TW294595B (enExample) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2291630A1 (en) * 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU9002598A (en) 1997-09-16 1999-04-05 Takeda Chemical Industries Ltd. Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
EP1147112B1 (en) 1999-01-29 2003-10-29 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
IL155163A0 (en) * 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
CA2456985A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
UA78548C2 (en) 2002-03-29 2007-04-10 Janssen Pharmaceutica Nv Radiolabelled quinoline and quinolinone derivatives and use thereof as metabotropic ligands of glutamate receptor
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
CA2507027C (en) * 2002-11-22 2012-05-08 Mitsubishi Pharma Corporation Isoquinoline compounds and medicinal use thereof
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
AU2004295058B9 (en) * 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
EA011211B1 (ru) * 2003-11-20 2009-02-27 Янссен Фармацевтика Н. В. 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
PT2277865E (pt) 2003-12-03 2015-02-05 Ym Biosciences Australia Pty Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos
EP1709012B1 (en) * 2003-12-05 2015-07-29 Janssen Pharmaceutica NV 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose)polymerase inhibitors
WO2005058843A1 (en) * 2003-12-10 2005-06-30 Janssen Pharmaceutica N.V. Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
NZ551775A (en) 2004-06-01 2010-12-24 Univ Virginia Dual small molecule inhibitors of cancer and angiogenesis
JP4852540B2 (ja) 2004-06-30 2012-01-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parp阻害剤としてのフタラジン誘導体
WO2006003150A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
SG154432A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
ES2545382T3 (es) * 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
RU2008110955A (ru) 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
PT1984333E (pt) 2006-02-03 2012-07-16 Bionomics Ltd Benzofuranos, benzotiofenos, benzoselenofenos e indóis substituídos e sua utilização como inibidores da polimerização da tubulina
RU2008136784A (ru) 2006-02-15 2010-03-20 Абботт Лаборэтриз (Us) Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HRP20120346T1 (hr) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Derivati kinolinona kao parp i tank inhibitori
ES2505091T3 (es) * 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina

Similar Documents

Publication Publication Date Title
US10173998B2 (en) Antifungal compound process
AU2015231234B2 (en) Antifungal compound process
JP2017533968A5 (enExample)
JP2013542261A5 (enExample)
JP2014513110A5 (enExample)
JP2019517487A5 (enExample)
JP2014511892A5 (enExample)
JP2016516043A5 (enExample)
JP2015503507A5 (enExample)
JP2009523760A5 (enExample)
JP2011509309A5 (enExample)
JP2018517746A5 (enExample)
JP2017537949A5 (enExample)
JP2015501833A5 (enExample)
JP2016513696A5 (enExample)
JP2013544860A5 (enExample)
EP3119746A1 (en) Antifungal compound process
AU2015231216A1 (en) Antifungal compound process
JP2011509302A5 (enExample)
JP2013527847A5 (enExample)
JP2020502230A5 (enExample)
EP3452475A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
AU2013328609B2 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
JP2023550902A5 (enExample)
JP2010514734A5 (enExample)